Based on reports on efficacy of FGFR inhibitors in brain tumors from basket trials e.g. of the FGFR1-4 inhibitor futibatinib [46], these patients were treated with FGFR1-3 inhibitor pemigatinib which in Europe is approved for the treatment of adults with locally advanced/metastatic cholangiocarcinoma with fusion or rearrangement of FGFR2. Unfortunately, both patients did not benefit from pemigatinib with early tumor progression after three/two months (Figs. 3A, 5B). Here, FGFR1 is linked to neoplasm.